Silexion Therapeutics Corp (SLXN) shareholders
Close on Nov 18, 2026Market cap $868.40KP/E –Yield –
Ownership
Who owns Silexion Therapeutics's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Guangzhou Sino-Israel Bio-Industry Investment Fund (LLP) Joint filing with Avner Lushi (13.80%), Shlomo Noy (13.80%) | 1,987,082 | 13.80% | 13D (active) | Aug 15, 2024 |
| Ilan Levin Joint filing with Moringa Sponsor, LP (17.70%), Moringa Partners Ltd (17.70%) | 1,954,056 | 17.70% | 13D (active) amendment | Sep 18, 2026 |
| Moringa Partners Ltd Joint filing with Ilan Levin (10.60%), Moringa Sponsor, LP (25.00%) | 1,391,827 | 10.60% | 13D (active) amendment | Jul 30, 2026 |
| Moringa Sponsor, LP Joint filing with Moringa Partners Ltd (32.99%), Ilan Levin (32.99%) | 1,382,346 | 32.99% | 13D (active) amendment | May 14, 2026 |
| CVI Investments, Inc. Joint filing with Heights Capital Management, Inc. (8.50%) | 339,000 | 8.50% | 13G (passive) | Jan 15, 2025 |
| Mitchell P. Kopin Joint filing with Daniel B. Asher (9.40%), Intracoastal Capital LLC (9.40%) | 325,000 | 9.40% | 13G (passive) amendment | Dec 31, 2025 |
| Daniel B. Asher Joint filing with Mitchell P. Kopin (9.99%), Intracoastal Capital, LLC (9.99%) | 244,771 | 9.99% | 13G (passive) | Sep 11, 2025 |
| Easton Jeff Joint filing with Lind Global Fund III LP (6.40%), Lind Global Partners III LLC (6.40%) | 212,500 | 6.40% | 13G (passive) amendment | Sep 30, 2025 |
| Lincoln Alternative Strategies LLC | 131,250 | 6.18% | 13G (passive) | Sep 12, 2025 |
| Orca Capital AG | 131,250 | 6.20% | 13G (passive) | Sep 11, 2025 |
| The Goldman Sachs Group, Inc. Joint filing with Goldman Sachs & Co. LLC (6.60%) | 112,242 | 6.60% | 13G (passive) | Dec 31, 2024 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Ilan Hadar | Chairman and CEO, Director | 16,547 | Jun 8, 2026 |
| Mitchell Shirvan | CSO and CDO | 8,789 | Jun 8, 2026 |
| Hadar Mirit Horenshtein | CFO and Secretary | 12,515 | Jun 8, 2026 |
| Shlomo Noy | Director | 25,399 | Feb 25, 2026 |
| Amnon Peled | Director | 8,237 | Feb 23, 2026 |
| Ruth Alon | Director | 10,228 | Feb 23, 2026 |
| Avner Lushi | Director | 25,399 | Feb 23, 2026 |
| Dror Yosef Abramov | Director | 10,180 | Feb 23, 2026 |
| Ilan Levin | Director, 10% owner | – | Jan 27, 2026 |
| Moringa Sponsor, LP | 10% owner | 458,452 | Jan 27, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mitchell Shirvan CSO and CDO | Jun 4, 2026 | Award | +6,000 | – | – | 8,789 |
| Hadar Mirit Horenshtein CFO and Secretary | Jun 4, 2026 | Award | +7,500 | – | – | 12,515 |
| Ilan Hadar Chairman and CEO, Director | Jun 4, 2026 | Award | +10,000 | – | – | 16,547 |
| Mitchell Shirvan CSO and CDO | Mar 26, 2026 | Sale | −22,818 | $1.36 | $31.03K | 27,889 |
| Shlomo Noy Director | Feb 20, 2026 | Award | +9,091 | – | – | 25,399 |
| Ruth Alon Director | Feb 20, 2026 | Award | +9,091 | – | – | 10,228 |
| Hadar Mirit Horenshtein CFO and Secretary | Feb 20, 2026 | Award | +49,726 | – | – | 50,146 |
| Avner Lushi Director | Feb 20, 2026 | Award | +9,091 | – | – | 25,399 |
| Dror Yosef Abramov Director | Feb 20, 2026 | Award | +9,091 | – | – | 10,180 |
| Ilan Hadar Chairman and CEO, Director | Feb 20, 2026 | Award | +64,350 | – | – | 65,471 |
| Amnon Peled Director | Feb 20, 2026 | Award | +7,576 | – | – | 8,237 |
| Mitchell Shirvan CSO and CDO | Feb 20, 2026 | Award | +49,726 | – | – | 50,707 |
| Moringa Sponsor, LP 10% owner | Sep 15, 2025 | Award | +450,000 | $4.00 | $1.80M | 456,970 |
| Moringa Sponsor, LP 10% owner | Aug 7, 2025 | Other | −5,550 | – | – | 6,970 |
| Dror Yosef Abramov Director | Feb 9, 2025 | Award | +794 | – | – | 794 |
| Avner Lushi Director | Feb 9, 2025 | Award | +1,587 | – | – | 1,587 |
| Amnon Peled Director | Feb 9, 2025 | Award | +661 | – | – | 661 |
| Ruth Alon Director | Feb 9, 2025 | Award | +794 | – | – | 794 |
| Shlomo Noy Director | Feb 9, 2025 | Award | +1,587 | – | – | 1,587 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Silexion Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,853,952 shares on Sep 30, 2026 over the last 90 days.
See a number that looks wrong?